Vistagen Therapeutics (VTGN) Interest Coverage Ratio (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Interest Coverage Ratio of 3343.4 for Q1 2026, down 52419.37% sequentially from 6.37 in Q3 2025, and down 18352.71% YoY from N/an in Q1 2025.
Vistagen Therapeutics (VTGN) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Interest Coverage Ratio for 15 years, with the latest figure at 3343.4 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 18352.71% year-over-year to 3343.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.59 (down 67.23% YoY) and the FY2026 annual result came in at 0.77, down 7.21% from the prior year.
- Interest Coverage Ratio slipped to 3343.4 in Q1 2026 per VTGN's latest filing, from 6.37 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.19 in Q1 2024 and troughed at 3343.4 in Q1 2026.
- A 5-year average of 424.87 and a median of 27.89 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2026: Interest Coverage Ratio jumped 99.62% in 2024, then tumbled 18352.71% in 2026.
- Over 5 years, Interest Coverage Ratio stood at 16.55 in 2022, then advanced by 11.56% to 14.64 in 2023, then plunged by 6786.61% to 1008.0 in 2024, then jumped by 99.37% to 6.37 in 2025, then slumped by 52419.37% to 3343.4 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 3343.4, 6.37, and 254.9 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,343.40 |
| Sep 30, 2025 | -6.37 |
| Jun 30, 2025 | -254.90 |
| Mar 31, 2025 | -18.12 |
| Dec 31, 2024 | -1,008.00 |
| Sep 30, 2024 | -1,094.38 |
| Jun 30, 2024 | -28.75 |
| Mar 31, 2024 | -0.19 |
| Jun 30, 2023 | -14.64 |
| Mar 31, 2023 | -50.00 |
| Dec 31, 2022 | -16.55 |
| Sep 30, 2022 | -5.03 |
| Jun 30, 2022 | -27.03 |
| Mar 31, 2022 | -80.84 |
| Dec 31, 2021 | -2.65 |
| Sep 30, 2021 | -12.68 |
| Jun 30, 2021 | -34.29 |
| Mar 31, 2021 | -30.94 |
| Dec 31, 2020 | -6.72 |
| Sep 30, 2020 | -2.48 |